Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
FDA Drug Information Soundcast in Clinical Oncology (DISCO) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.
Latest Drug Information Soundcasts
Title | Date | Link to Podcast | Link to Transcript |
---|---|---|---|
FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur |
May 16, 2017 | Run Time: 00:3:19 |
Transcript |
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer |
May 17, 2017 | Run Time: 00:5:13 |
Transcript |
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer |
May 18, 2017 | Transcript | |
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma |
May 22, 2017 | Transcript | |
FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval |
May 30, 2017 | Transcript | |
FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer. |
July 25, 2017 | Run Time: 00:9:00 |
Transcript |
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. |
July 28, 2017 | Run Time: 00:6:00 |
Transcript |
FDA D.I.S.C.O.: L-glutamine for sickle cell disease FDA medical oncologists discuss the July 7, 2017, approval of l-glutamine to reduce the acute complications of sickle cell disease. |
August 17, 2017 | Run Time: 00:5:29 |
Transcript |
FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia FDA medical oncologists discuss the Aug. 3, 2017, approval of Vyxeos for treatment of acute myelogenous leukemia. |
September 15, 2017 | Run Time: 00:4:59 |
Transcript |
FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer FDA medical oncologists discuss the Sept 14, 2017, approval of MVASI, the first biosimilar approved in the US for the treatment of cancer. |
December 21, 2017 | Run Time: 00:8:29 |
Transcript |
FDA D.I.S.C.O.: First FDA approval of a CAR T-cell immunotherapy FDA medical oncologists discuss the first approval of a chimeric antigen receptor (CAR) T-cell immunotherapy. |
February 23, 2018 | Run Time: 00:5:59 |
Transcript |
FDA D.I.S.C.O.: Nivolumab for adjuvant treatment of patients with melanoma FDA medical oncologists discuss the December 20, 2017, approval of nivolumab for the adjuvant treatment of patients with melanoma. |
February 26, 2018 | Run Time: 00:5:00 |
Transcript |
FDA D.I.S.C.O.: A new drug approval for non-metastatic castration-resistant prostate cancer FDA medical oncologists discuss the February 14, 2018, approval of apalutamide for the treatment of non-metastatic castration-resistant prostate cancer. |
May 3, 2018 | Run Time: 00:4:59 |
Transcript |
FDA D.I.S.C.O.: A supplemental drug approval for the adjuvant treatment of high risk advanced renal cell cancer FDA medical oncologists discuss the November 2017 approval of sunitinib for the adjuvant treatment of patients with renal cell carcinoma who are at high risk of recurrence following a nephrectomy. |
August 16, 2018 | Run Time: 00:5:29 |
Transcript |
FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer FDA medical oncologists discuss the January 12, 2018, approval of olaparib, the first PARP inhibitor approved for the treatment of patients with metastatic breast cancer with a germline BRCA mutation. |
October 2, 2018 | Run Time: 00:5:29 |
Transcript |
FDA D.I.S.C.O.: A new drug approval for IDH1 positive relapsed or refractory Acute Myeloid Leukemia FDA medical oncologists discuss the July 2018 approval of ivosidenib for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. |
October 18, 2018 | Run Time: 00:6:29 |
Transcript |
FDA D.I.S.C.O.: FDA approval of moxetumomab pasudotox-tdfk for relapsed or refractory hairy cell leukemia FDA medical oncologists discuss the Sept. 13, 2018, approval of moxetumomab pasudotox-tdfk for the treatment of patients with relapsed or refractory hairy cell leukemia. |
November 29, 2018 | Run Time: 00:8:13 |
Transcript |
FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma FDA medical oncologists discuss the September 28, 2018, approval of cemiplimab-rwlc for the treatment of select patients with cutaneous squamous cell carcinoma. |
November 30, 2018 | Run Time: 00:8:17 |
Transcript |
FDA D.I.S.C.O.: FDA approval of larotrectinib for advanced malignancies with NTRK gene fusion FDA medical oncologists discuss the Nov. 26, 2018, accelerated approval of larotrectinib for adult and pediatric patients. |
December 13, 2018 | Run Time: 00:7:29 |
Transcript |
FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma FDA medical oncologists discuss the January 14, 2019, approval of cabozantinib for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. |
March 12, 2019 | Run Time: 00:5:29 |
Transcript |
FDA D.I.S.C.O.: FDA approval of Cablivi for acquired thrombotic thrombocytopenic purpura |
April 12, 2019 | Run Time: 00:7:59 |
Transcript |